StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Despite the stock dip, long-term revenue growth remains strong. Historical examples show stock recovery post-revenue surprises.
What happened, with direct paths to the underlying reporting
iRhythm expects 2025 revenue above $740 million with strong Q4 performance. 2026 revenue forecast of $870-$880 million shows 17-18% growth. Stock fell 20% due to Zio MCT launch delay to 2027. Analyst believes stock weakness is overblown; recommends buying. iRhythm maintains Outperform rating, expects solid long-term growth.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.